🇺🇸

US SEC Filing Intelligence

· daily

US Executive Officer Management Changes SEC — March 26, 2026

Across 43 filings on USA executive and director changes from March 26, 2026, the dominant theme is leadership transitions with 22 appointments (experienced hires in energy, tech, banking) versus 18 resignations/departures, mostly neutral sentiment but positive on strategic hires like Vitesse Energy's new CEO and Bloom Energy's CFO. Period-over-period data limited but notable: Interlink Electronics Q4 2025 revenue -4.5% YoY to $2.853M, gross margin -790 bps to 31.7%, though FY revenue +1.8% to $11.89M with net loss improved -19% to -$1.615M. No widespread insider trading or capital allocation shifts, but compensation enhancements (e.g., Meritage Homes CEO target $4M cash +$6M equity, Alight TVR awards up to 8.25M shares) signal retention focus. Positive hires boost conviction in growth sectors like AI/energy (Bloom, 3D Systems), while sudden CFO exits (RetinalGenix, MetroCity) flag risks. Portfolio implication: Monitor energy/utilities (6 filings) for stability, tech/biotech (12 filings) for innovation acceleration; overall neutral-to-positive for long-term value via succession planning.

43 high priority 43 total filings
· daily

US Bankruptcy Chapter 11 Insolvency SEC Filings — March 26, 2026

Broad Street Realty, Inc., the sole filing in this USA Bankruptcy & Insolvency stream, voluntarily petitioned for Chapter 7 bankruptcy on March 20, 2026, in the U.S. Bankruptcy Court for the District of Delaware (Case No. 26-10398-KBO), signaling total liquidation and cessation as a going concern. George L. Miller was appointed Chapter 7 Trustee to oversee asset liquidation and creditor payments, immediately stripping the Board of Directors and executives of all authority. CFO Alexander Topchy resigned effective the same date, underscoring acute management distress amid the collapse. No period-over-period financial trends or forward-looking guidance are viable post-filing, as operations end; sentiment is uniformly negative with 10/10 materiality. This development implies imminent equity wipeout, with portfolio implications for real estate exposure: delisting likely, zero recovery for shareholders. Overarching theme: isolated but extreme insolvency event highlights vulnerability in commercial realty amid presumed prior deteriorating metrics like rising debt or occupancy declines.

1 high priority 1 total filings
· daily

US Corporate Board Director Changes SEC Filings — March 26, 2026

Across 43 filings on USA Board Room Changes from March 26, 2026, the dominant theme is elevated C-suite and board turnover, with 18 CFO/CAO/Principal Accounting Officer changes (e.g., retirements, resignations, appointments), 12 CEO/President shifts, and 15+ board director additions/resignations/not standing for re-election, signaling proactive refreshes amid strategic pivots. Positive sentiment prevails in 12 cases (e.g., experienced hires in energy/tech like Vitesse CEO Jamie Benard, Bloom CFO Simon Edwards), neutral in 26, negative/mixed in 5, with materiality averaging 6/10 and peaking at 9/10 for Vitesse, Apimeds dispute, Skywater transaction. Sparse period-over-period data shows Interlink Electronics Q4 2025 revenue -4.5% YoY ($2.853M vs $2.986M), FY +1.8% ($11.89M), gross margins -780bps Q4/-260bps FY, highlighting product mix pressures; no broad deteriorating trends but isolated losses improving FY net loss -18.6% YoY. Forward-looking catalysts cluster around May 2026 AGMs (Macy's May 15, Auburn May 12) and Q2 transitions (Vitesse May 1 CEO). Portfolio implications: Bullish for leadership upgrades in growth sectors (energy, tech), bearish execution risks in finance CFO churn; monitor for insider conviction via post-change trading.

43 high priority 43 total filings
· daily

US Merger & Acquisition SEC Filings — March 26, 2026

The 8 filings highlight intense SPAC maneuvering amid M&A completions in niche sectors like crypto blockchain and industrial/pharma mergers, with 5/8 filings from blank-check companies (Soulpower, Launch One, Haymaker, IB, Metal Sky) showing extension efforts, financings, and governance changes versus 3 actual deal closures (Atlantic, Crypto Co, Enzon). Key trends include heavy SPAC redemptions (e.g., IB's $7.9M outflow leaving $8.2M trust) and sponsor support via notes/preferred stock, signaling prolonged hunts for targets; no broad YoY/QoQ financial trends reported but capital raises average ~$1.25M principal across notes/preferred for working capital/BC. Positive catalysts emerge from Crypto Co's milestone-based IP acquisition with 2026 blockchain launch and Enzon's all-stock merger (45/55 ownership split), boosting interoperability and operational scale. Mixed sentiment prevails (3 neutral, 2 positive, 1 mixed) with materiality skewed high (5/8 at 7-9/10) on deal-related filings, implying near-term volatility in SPACs but alpha in completed M&A. Portfolio-level pattern: SPACs face redemption pressures (1/5 with quantified $7.9M drain) versus accretive deals with no upfront dilution.

8 high priority 8 total filings
· monthly

US Pre-Market SEC Filings Roundup — March 26, 2026

Across 50 overnight SEC filings for March 25-26, 2026, FY2025 results dominate with mixed outcomes: 12/20 major 10-Ks showed revenue growth averaging +12% YoY (e.g., Lumexa +7.8%, Leef Brands +22.1%, TXO Partners +41.8%), but net losses widened in 8/20 cases amid impairments, higher expenses, and debt costs; REITs and BDCs exhibited portfolio stress with yields declining (BlackRock Multifamily 4.5%, AB Private Credit 9.58% vs 10.51%). SPAC/de-SPAC momentum is strong with 8 filings advancing mergers (Suncrete non-redemptions, Enhanced Games IPO path, Xanadu $500M proceeds), signaling M&A alpha in tech/AI/quantum. Capital allocation leans defensive: buybacks (Williams Sonoma $862M, News Corp $1B program), dividends stable, but leverage rose in energy (TXO +85%). Healthcare/imaging outperforms (Lumexa advanced procedures +14.2% Q4 YoY, leverage down to 3.5x), while banks face NIM expansion offset by provisions (United Security ROA - to 1.01%). Delistings (FiscalNote) and restatements (Genie Energy) flag risks; forward catalysts cluster in Q2 (proxies, earnings April-May). Overall, selective bullishness in growth niches amid broad profitability pressure, favoring de-SPACs and reiterated guidance plays pre-open.

35 high priority 15 medium 50 total filings
· daily

Biotech Small-Cap Approvals — March 25, 2026

Four neutral FDA approvals occurred in biotech small-caps from March 19-20, 2026: one original NDA for atomoxetine hydrochloride (MAP77 LLC) and three ANDAs for lidocaine hydrochloride (QUAGEN, VIWIT PHARM) and ephedrine sulfate (FRESENIUS KABI USA), all under standard review with no special designations or indications specified. A key pattern is duplication in lidocaine generics (2/3 ANDAs), signaling supply buildup in mature anesthetic markets. No high-impact innovation; routine events imply modest portfolio gains for sponsors amid commoditization risks.

4 total filings
· daily

New Drug Approvals (Original) — March 25, 2026

FDA approvals from March 19-20 (reported March 25) consist of four neutral original approvals under standard review, with no priority, breakthrough, or other designations—three ANDAs (75%) signaling routine generic entries and one NDA. A concentration of two lidocaine hydrochloride ANDAs (QUAGEN, VIWIT PHARM) on consecutive days highlights potential supply increase and competition in this molecule. Overall, low materiality for portfolios; generics-focused sponsors gain minor portfolio depth amid commoditized markets.

4 total filings
· daily

HHS & Healthcare Contracts Intelligence — March 25, 2026

HHS demonstrates sustained commitment to biodefense and vaccine R&D with $530M obligated across two long-term contracts: Emergent BioSolutions' $422M VIGIV deal (potential $706M ceiling) provides high revenue visibility through 2027-2029. Mount Sinai's $108M influenza research award (potential $151M) supports innovation but caps upside via cost-no-fee terms. Cross-cutting theme of unexercised options (~$328M combined) signals potential upside amid execution risks from extended timelines.

2 total filings
· daily

New Federal Contractors — March 25, 2026

This one-day snapshot of new federal contractor data is dominated by a $2.95B NASA/Caltech JPL contract (68% of total value), signaling sustained but neutral space R&D funding with limited equity upside due to nonprofit status. Four bullish signals highlight $1.13B in HHS health/pharma/IT and DHS/GSA security/IT contracts, offering reliable multi-year revenue to for-profits like Elevance Health, Emergent BioSolutions, Elbit Systems, and Pyramid Systems. Long-duration commitments (avg. end 2027+) provide visibility but concentrate risks in execution and subawards amid $1.3B unoutlayed.

7 total filings
· daily

Significant Contract Modifications ($10M+) — March 25, 2026

HHS dominates with $1.19B across four contracts (28% of total), signaling sustained federal health IT, biopharma, and R&D spending through 2027+. NASA's $2.95B Caltech JPL modification anchors 68% of volume but offers neutral equity impact as a nonprofit. Bullish signals in for-profit IT/services (Elevance, Emergent, ElbitAmerica, Pyramid) highlight $1.13B in reliable revenue ramps, with minimal outlays in newer awards indicating near-term cash flow acceleration.

7 total filings
· daily

Contract Deobligations Alert — March 25, 2026

Deobligations alert reveals $4.34B in major contract obligations dominated by NASA's $2.95B Caltech/JPL award (68% of total), signaling stable space R&D funding through 2028 but neutral equity impact as nonprofit. Four bullish signals ($1.13B total) highlight reliable revenue for Elevance Health, Emergent BioSolutions, ElbitAmerica, and Pyramid Systems in health IT/pharma, surveillance, and HUD IT through 2026-2030. HHS contracts aggregate ~$1.19B with long-term outlays, underscoring healthcare services resilience amid execution risks from firm-fixed pricing and subawards.

7 total filings
· daily

Contract Option Exercises — March 25, 2026

A $4.34B batch of contract option exercises is dominated by a single $2.95B NASA award to Caltech (68% of total), signaling sustained U.S. space R&D funding through 2028 but limited equity upside due to nonprofit status. Four bullish signals ($1.23B total) highlight reliable revenue for for-profit firms in health IT/pharma (Elevance, Emergent) and security/IT (ElbitAmerica, Pyramid), with performance extending to 2030. Long-term visibility tempers execution risks from firm-fixed-price structures and zero-outlay awards, prioritizing HHS/DHS exposure over neutral nonprofits.

7 total filings
· daily

NASA & Space Contracts Intelligence — March 25, 2026

NASA's $2.95B contract with Caltech for JPL operations signals sustained commitment to space R&D through 2028, with $2.43B already outlayed and $3.15B potential including options. Direct equity impacts are limited due to Caltech's nonprofit status, but underscores stability in NASA's FFRDC model for missions like Europa Clipper. Investors should monitor task order execution amid funding variability risks.

1 total filings
· daily

All HHS Contracts — March 25, 2026

HHS awarded $1.19B across 4 contracts in this period, with 68% ($928M) to for-profits signaling reliable multi-year revenue in IT services and biopharma stockpiling through 2027+. Bullish signals dominate for Elevance Health and Emergent BioSolutions due to high outlays (avg 55% obligated) and option upside to $858M total ceiling. Neutrals for nonprofits highlight steady R&D funding but cap investor upside amid subaward dependencies and execution risks to 2027.

4 total filings
· daily

Mega Contracts Monitor ($100M+) — March 25, 2026

HHS dominates with $1.19B across four contracts in IT services, biodefense pharma, and R&D support, signaling sustained federal health spending through 2027+. NASA's $2.95B JPL renewal underscores stable space R&D funding but limited equity upside due to nonprofit recipient. Bullish signals on for-profit contractors (Elevance Health, Emergent BioSolutions, ElbitAmerica) highlight reliable multi-year revenue amid neutral nonprofit exposures.

6 total filings
· daily

High-Value Federal Grants ($5M+) — March 25, 2026

A $4.34B batch dominated by a single $2.95B NASA/Caltech JPL contract (68% of total) underscores stable space R&D funding through 2028, but limited equity upside due to nonprofit status. Four bullish signals ($1.13B total) highlight revenue visibility in HHS IT/pharma and DHS/GSA security/IT via for-profits like Elevance Health, Emergent BioSolutions, ElbitAmerica, and Pyramid Systems, with contracts extending to 2030. Neutrals ($3.21B, mostly nonprofits) signal lower-risk but non-investable flows in health R&D; watch outlay execution lags ($0 outlay on two new awards) and long tenors exposing to funding shifts.

7 total filings
· daily

General Federal Contracts — March 25, 2026

Dominant $2.95B NASA obligation to Caltech (68% of total) confirms long-term space R&D stability but neutral equity impact as nonprofit. Bullish signals across $1.13B in health/pharma/IT (Elevance $505M, Emergent $422M) and security/IT (Elbit $105M, Pyramid $100M) highlight reliable fed revenue through 2026-2030. HHS contracts total $1.19B (28%), signaling healthcare services momentum amid $4.34B overall obligations with 4 bullish, 3 neutral signals.

7 total filings
· daily

All NASA Contracts — March 25, 2026

NASA's $2.95B obligation to Caltech for JPL operations (with $2.43B outlayed and $3.15B potential including options) through 2028 confirms stable, non-competitive funding for space R&D including Europa Clipper, but as a nonprofit FFRDC, offers no direct equity exposure. This sole contract in the period highlights concentrated reliance on JPL for critical missions amid a 10-year term. Investors should monitor task order issuances and option exercises for indirect sector signals.

1 total filings